The financials
Innoviva, Inc. by the numbers
Innoviva, Inc. (INVA) reported revenue of $98M in Q1 2026 (quarter ended March 31, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 77% and net income of $187M (190% of revenue). For the full year FY2025, revenue was $411M (+15% year on year) and net income $271M. Its largest product in 2026-Q1 was Royalty at $55M, 56% of the disclosed total, just ahead of Giapreza at 21%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $98M | $89M | +11% |
| Gross profit | $76M | $73M | +3.4% |
| Operating income | $38M | $41M | −7.9% |
| Net income | $187M | −$47M | to a profit |
| Diluted EPS | $2.22 | −$0.74 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Royalty | $55M | 56% |
| Giapreza | $20M | 21% |
| Xacduro | $18M | 18% |
| Xerava | $2.6M | 2.7% |
| License And Other | $1.5M | 1.5% |
| ZEVTERA | $438K | 0.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $98.0M (-10%)
License And Other grew +167% year on yearCost Reimbursement -100% year on year
Segment Latestquarter on quarteryear on year
- Royalty$55.2M$55.2MQoQ -7.9%year on year -4.6%-7.9%-4.6%
- Giapreza$20.2M$20.2MQoQ +9.6%year on year +11%+9.6%+11%
- Xacduro$18.1M$18.1MQoQ -24%year on year +132%-24%+132%
- Xerava$2.6M$2.6MQoQ -46%year on year -38%-46%-38%
- License And Other$1.5M$1.5MQoQ +139%year on year +167%+139%+167%
- ZEVTERA$438.0K$438.0KQoQ +288%year on year -+288%-
- Cost Reimbursement$0.00$0.00QoQ -100%year on year -100%-100%-100%
Biotechnology
Ranks #24 of 145 by Smart Score